en · de · es · fr · pt
cjc-1295-notes.peptides7501.com › Info › Analytical Characterization And Storage — Beginner to Advanced

Analytical Characterization And Storage — Beginner to Advanced

By Editorial Desk · published 2026-01-03 · last reviewed 2026-02-16 · Info

GRF(1-29) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-02-16. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Characterization and Storage

Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Receptor Action and Pharmacokinetics

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

Cjc-1295 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderAssessed by visual inspection under ordinary light
Primary analytical methodReversed-phase liquid chromatographyPurity estimated from peak area at 214 nm
Confirmatory methodMass spectrometryObserved mass compared with calculated value
Powder storage temperatureMinus 20 degrees CelsiusMinus 80 for extended archival periods
Solution stabilityHours to days at 2 to 8 degrees CelsiusInfluenced by pH, buffer, and concentration

Compound Identity and Development History

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Related pages on this site

Receptor Action and Clearance

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

Reference notes

=== The efficiency of EI === Increasing the electron ionization process is done by increasing the ionization efficiency. In order to achieve higher ionization efficiency there should be an optimized filament current, emission current, and ionizing current. The current supplied to the filament to heat it to incandescent is called the filament current. The emission current is the current measured between the filament and the electron entry slit. The ionizing current is the rate of electron arrival at the trap. It is a direct measure of the number of electrons in the chamber that are available for ionization. The sample ion current (I+) is the measure of the ionization rate. This can be enhanced by manipulation of the ion extraction efficiency (β), the total ionizing cross section (Qi), the effective ionizing path length (L), the concentration of the sample molecules([N]) and the ionizing current (Ie). The equation can be shown as follows:

At 05:21 Venezuelan Standard Time (VET) or 04:21 Eastern Standard Time (ET), Trump announced that Maduro and Flores had been captured and flown out of the country. The capture was undertaken by the US Army's Delta Force, with on-the-ground intelligence provided by the CIA. Trump posted a photograph on his Truth Social account of Maduro on board USS Iwo Jima, showing him blindfolded, with soundproof headphones and a gray Nike sweatsuit, holding a plastic water bottle. According to US Secretary of State Marco Rubio, Maduro was "arrested" and would face criminal charges in the US. Nahum Fernández, leader of the ruling United Socialist Party of Venezuela, said Maduro and Flores were captured at Fort Tiuna; they reportedly slept at multiple locations and had a "fortress-like" compound at Fort Tiuna. Delcy Rodríguez confirmed that both Maduro and Flores were missing and demanded confirmation they were alive via an audio message on state television. According to Reuters sources, Rodríguez was in Russia on 3 January 2026. While other rumors indicate she was vacationing in Margarita Island. Other reports indicated that Rodríguez was in Caracas. Shortly before 18:00 VET (17:00 EST), the airplane carrying Maduro and Flores landed at Stewart Air National Guard Base in New York. He was seen walking off the jet, surrounded by federal agents, before entering a hangar.

=== Morphology === "Candidatus Magnetoglobus multicellularis" is an obligately multicellular bacteria without a unicellular stage in its lifecycle. It typically consists of 10–40 bacterial cells in an organised spherical structure surrounding an acellular compartment. The entire organism has a diameter of approximately 3 to 12 micrometres. Individual cells are elongated into a pyramidal shape, with the narrow apex facing the acellular compartment in the centre. The outward-facing surface of each cell houses numerous flagella. The cells are all tightly joined by highly specialised intercellular junctions, similar to those found in eukaryotic multicellular organisms. The exterior of the organism features a cellulose matrix that plays a role in cell adhesion and structural integrity.

=== Pharmacokinetics === Prednisolone has a relatively short half-life, ranging 2–4 hours. It also has a large therapeutic window, considering the dosage required to produce a therapeutic effect is a few times higher than what the body naturally produces. Prednisolone is 70–90% plasma protein bound, it binds to proteins such as albumin. Both prednisolone phosphate and prednisolone acetate go through ester hydrolysis in the body to form prednisolone. It subsequently undergoes the usual metabolism of prednisolone. Concomitant use of prednisolone and strong CYP3A4 inhibitors such as ketoconazole is shown to cause a rise in plasma prednisolone concentrations by about 50% owing to a diminished clearance. Prednisolone predominantly undergoes kidney elimination and is excreted in the urine as sulphate and metabolites of glucuronide conjugate.

Sources: en.wikipedia.org

Reference notes

== Missile Impact Location System == From 1958 through 1960 the United States installed the Missile Impact Location System (MILS) in the Navy-managed Pacific Missile Range, later the Air Force–managed Western Range, to localize the splashdowns of test missile nose cones. MILS was developed and installed by the same entities that had completed the first phase of the Atlantic and U.S. West Coast SOSUS systems. A MILS installation, consisting of both a target array for precision location and a broad ocean area system for good positions outside the target area, was installed at Eniwetok as part of the system supporting intercontinental ballistic missile (ICBM) tests. Other Pacific MILS shore terminals were at the Marine Corps Air Station Kaneohe Bay supporting intermediate-range ballistic missile (IRBM) tests with impact areas northeast of Hawaii and the other ICBM test support systems at Midway Island and Wake Island.

=== Disease association === Genetic variants and haplotypes (i.e., allotypes) of ERAP1 have been associated with a wide variety of inflammatory conditions, infectious diseases, and cancer. In particular, ERAP1 is a major risk gene identified in genome-wide association studies of MHC-I associated inflammatory conditions (or "MHC-I-opathies"), including Ankylosing Spondylitis, Bechet's disease, Birdshot Uveitis, and Psoriasis. In these conditions, ERAP1 is often in epistasis with the primary risk MHC-I allele. Other disease associations include insulin dependent Diabetes Mellitus and Multiple Sclerosis. Historically, ERAP1 gene associations were first reported in Hypertension. Emerging evidence links ERAP1 SNVs to cancer development, and susceptibility to infectious disease, such as ERAP1 SNVs that modify the resistance to influenza virus infection.

Physicists in the 1920s believed that the atomic nucleus contained protons plus a number of "nuclear electrons" that reduced the overall charge. These "nuclear electrons" were distinct from the electrons that orbited the nucleus. This incorrect hypothesis would have explained why the atomic numbers of the elements were less than their atomic weights, and why radioactive elements emit electrons (beta radiation) in the process of nuclear decay. Rutherford even hypothesized that a proton and an electron could bind tightly together into a "neutral doublet". Rutherford wrote that the existence of such "neutral doublets" moving freely through space would provide a more plausible explanation for how the heavier elements could have formed in the genesis of the Universe, given that it is hard for a lone proton to fuse with a large atomic nucleus because of the repulsive electric field. In 1928, Walter Bothe observed that beryllium emitted a highly penetrating, electrically neutral radiation when bombarded with alpha particles. It was later discovered that this radiation could knock hydrogen atoms out of paraffin wax. Initially it was thought to be high-energy gamma radiation, since gamma radiation had a similar effect on electrons in metals, but James Chadwick found that the ionization effect was too strong for it to be due to electromagnetic radiation, so long as energy and momentum were conserved in the interaction.

Sources: en.wikipedia.org

Frequently asked questions

How is sample identity confirmed?

Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.

Does a lyophilized powder require cold storage?

Dry powder is markedly more stable than solution and is usually held frozen and desiccated. Room temperature exposure over days degrades it more slowly than most people assume, but long-term integrity favors freezer storage. Light protection is recommended regardless of temperature.

Why do purity values differ between suppliers?

Methods, columns, gradients, and detection wavelengths are not standardized across laboratories. Some figures describe only the main peak area at one wavelength and ignore water, salts, or counter-ions. Without stated conditions, comparing reported percentages across sources is unreliable.

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Network